Study on Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia.
A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia
Sponsor: Dompé Farmaceutici S.p.A
A PHASE3 clinical study on Pneumonia, Viral, this trial is completed. The trial is conducted by Dompé Farmaceutici S.p.A and has accumulated 7 data snapshots since 2021. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Feb 2022 — Jul 2024 [monthly]
Completed PHASE3
Status: Recruiting → Completed
-
Oct 2021 — Feb 2022 [monthly]
Recruiting PHASE3
▶ Show 2 earlier versions
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jun 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE3
First recorded
Feb 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Dompé Farmaceutici S.p.A
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bologna, Italy , Genova, Italy , Greenwood, United States , L’Aquila, Italy , Milan, Italy , Monza, Italy , Napoli, Italy , Roma, Italy , Varese, Italy , Verona, Italy and 1 more location